Lilly bets $7.8B on sleep drugs beyond obesity

Eli Lilly is making a substantial $7.8 billion investment to expand its pharmaceutical portfolio beyond obesity treatments into the sleep disorder market. The acquisition of Centessa provides Lilly with a significant entry point into narcolepsy treatments and a promising pipeline of novel wakefulness-promoting drugs. This strategic move diversifies Lilly's therapeutic focus and aims to capture a growing segment of the pharmaceutical market, leveraging its research and development capabilities for new growth avenues.